Vascular Inflammation and Cholesterol Lowering Therapy
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02941016 |
Recruitment Status :
Withdrawn
(Logistic reasons)
First Posted : October 21, 2016
Last Update Posted : October 14, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Lipid Lowering, Vascular Inflammation | Drug: Evolocumab or Alirocumab | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 0 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Other |
Official Title: | Vascular Inflammation and Cholesterol Lowering Therapy |
Study Start Date : | October 2016 |
Estimated Primary Completion Date : | October 2020 |
Actual Study Completion Date : | October 1, 2020 |

Arm | Intervention/treatment |
---|---|
Experimental: Lipid lowering |
Drug: Evolocumab or Alirocumab
All patients are treated with PCSK-9 inhibitors (Evolocumab or Alirocumab) to lower cholesterol |
- Change in vascular inflammation [ Time Frame: 12 weeks ]Change in standard uptake value (SUV) of flourdeoxyglucose (FDG) before and after initiation of lipid lowering therapy

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- treatment with PCSK-9 inhibitors
Exclusion Criteria:
- Infection Pregnancy Severe claustrophobia Weight >140 kg

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02941016
Denmark | |
Rigshospitalet | |
Copenhagen, Denmark |
Principal Investigator: | Rasmus S Ripa, MD, DMSc | Rigshospitalet, Denmark |
Responsible Party: | Rasmus S. Ripa, Staff Physician, Rigshospitalet, Denmark |
ClinicalTrials.gov Identifier: | NCT02941016 |
Other Study ID Numbers: |
0002 |
First Posted: | October 21, 2016 Key Record Dates |
Last Update Posted: | October 14, 2020 |
Last Verified: | October 2020 |
Inflammation Pathologic Processes Evolocumab Anticholesteremic Agents |
Hypolipidemic Agents Antimetabolites Molecular Mechanisms of Pharmacological Action Lipid Regulating Agents |